- Abstract:
-
Alemtuzumab (Campath-1H) has been widely used for T-cell depletion following both conventional and reduced-intensity conditioning allografts. We studied the impact of alemtuzumab used in vivo and in vitro on infections, immune reconstitution, and allograft outcome. The use of alemtuzumab in vivo following reduced-intensity conditioning and unrelated donor conventional transplantation was associated with durable engraftment and significant reduction in graft-versus-host disease (GVHD) but at t...
Expand abstract - Publication status:
- Published
- Journal:
- Transplantation proceedings
- Volume:
- 36
- Issue:
- 5
- Pages:
- 1225-1227
- Publication date:
- 2004-06-05
- DOI:
- EISSN:
-
1873-2623
- ISSN:
-
0041-1345
- URN:
-
uuid:d2c17132-aef2-4c9b-b2d5-dbf51fdc5344
- Source identifiers:
-
9804
- Local pid:
- pubs:9804
- Copyright date:
- 2004
Journal article
Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?
Actions
Authors
Bibliographic Details
Item Description
Terms of use
Metrics
Altmetrics
Dimensions
If you are the owner of this record, you can report an update to it here: Report update to this record